Emerging biotechnologies: full report - Nuffield Council on Bioethics
Emerging biotechnologies: full report - Nuffield Council on Bioethics
Emerging biotechnologies: full report - Nuffield Council on Bioethics
Create successful ePaper yourself
Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.
E m e r g i n g b i o t e c h n o l o g i e s<br />
2011-15 delivery plan 7.42<br />
addressing societal challenges 6.36, 7.53<br />
general structure 7.52<br />
public-good research 9.13<br />
biotechnology boom 7.4, 9.5<br />
biotechnology wager 1.1–1.3, 1.34, 4.9, 6.36,<br />
10.4<br />
bioterrorism Box 3.1, 8.10<br />
botulinum toxin 3.9<br />
bricolage 9.35<br />
British Heart Foundati<strong>on</strong> 7.18<br />
British In Vitro Diagnostics Associati<strong>on</strong> 8.25<br />
business see commercial firms; industry<br />
Cabinet minister, proposed new 7.56, 10.17<br />
Cambridge Antibody Technology 7.4, 9.3<br />
cancer medicines 2.21, 2.27, 3.9, 9.51, Box 1.1<br />
Cancer Research UK 7.18<br />
candour, virtue of 4.50–4.51<br />
carb<strong>on</strong> tax 9.70<br />
Cartagena Protocol <strong>on</strong> Biosafety 8.6<br />
cauti<strong>on</strong><br />
in approach to regulati<strong>on</strong> 8.33–8.38, 8.46<br />
virtue of 4.53–4.55, 8.34, 8.38<br />
cells, synthetic 2.20, 2.37, Box 3.2<br />
cellular <str<strong>on</strong>g>biotechnologies</str<strong>on</strong>g> 2.5–2.6<br />
change, technological 3.22–3.25<br />
charities<br />
funding of research 6.14, 7.5, 7.18<br />
governance 7.57–7.58<br />
provisi<strong>on</strong> of public goods 4.8<br />
research policy 7.18–7.19<br />
steering directi<strong>on</strong> of research 6.22<br />
Chief Scientific Advisor, UK 6.36, 7.8<br />
chimeric animals 3.19<br />
chlorofluorocarb<strong>on</strong>s (CFCs) Box 1.1, 3.8<br />
choices<br />
c<strong>on</strong>tingent c<strong>on</strong>diti<strong>on</strong>s 1.21<br />
framing effects 3.34, 3.37, Box 3.4<br />
rati<strong>on</strong>al 3.21<br />
social 5.59–5.60<br />
Christianity 4.11–4.12<br />
citati<strong>on</strong> impact rankings 7.28<br />
citati<strong>on</strong> rates, UK research 7.24, 7.27–7.28<br />
citizen's juries 5.36, 5.43<br />
civil society groups 5.6, 5.16, 5.19<br />
climate change 1.9, 2.33<br />
clinical trials 4.49, 9.48–9.51, Box 9.3<br />
cl<strong>on</strong>ed embryos 3.20<br />
cl<strong>on</strong>ing, therapeutic 2.6<br />
closures, identifying 4.38–4.40, Box 4.1<br />
collaborative research 6.28, 6.61, 9.47<br />
collective acti<strong>on</strong>/interest<br />
public ethics 4.20–4.22<br />
public goods 4.8<br />
Collingridge dilemma 1.27–1.29, Box 1.2<br />
commercial exploitati<strong>on</strong> 9.1, 9.3<br />
commercial firms<br />
corporate social resp<strong>on</strong>sibility 9.53, 10.20<br />
funding of research 6.13, 7.5<br />
research settings 6.5<br />
steering research directi<strong>on</strong>s 6.27–6.35<br />
see also industry<br />
commercialisati<strong>on</strong> 9<br />
addressing the obstacles 9.45–9.70<br />
crossing the 'valley of death' 9.42–9.43<br />
example of failure 8.13<br />
incentivising 9.55–9.70, 10.21<br />
intellectual property rights limiting 9.17,<br />
9.21–9.41<br />
rates of patents 3.5<br />
recommendati<strong>on</strong>s 9.53, 9.56, 10.20–10.21<br />
social value and 9.52–9.54, 9.56, 9.71–<br />
9.72, 10.21<br />
'UK is bad at' claim 7.23–7.32<br />
see also intellectual property rights<br />
commercial purpose 9.1<br />
comm<strong>on</strong> good 4.17–4.18<br />
communicable diseases 1.10<br />
communicati<strong>on</strong>, by researchers 5.34, 6.50–<br />
6.54, 10.10<br />
communitarian turn 4.20<br />
competence, technical 4.51, 5.31, 5.53–5.54<br />
competitiveness, framing research policy 7.3<br />
complexity<br />
natural systems 4.13–4.14<br />
normative 4.34–4.37<br />
computati<strong>on</strong>al metaphors 2.37<br />
computers, superintelligent 3.19<br />
c<strong>on</strong>sensus, through public engagement 5.36,<br />
5.43<br />
c<strong>on</strong>sensus c<strong>on</strong>ferences 5.36, 5.43<br />
c<strong>on</strong>sortia 9.49, Box 9.3<br />
c<strong>on</strong>tingency, and its c<strong>on</strong>sequences 1.19–1.33<br />
c<strong>on</strong>tingent c<strong>on</strong>diti<strong>on</strong>s 1.20–1.23<br />
c<strong>on</strong>traceptive pill 3.8<br />
Cooksey <str<strong>on</strong>g>report</str<strong>on</strong>g> (2006) 9.42<br />
cooperative research see collaborative<br />
research<br />
corporate social resp<strong>on</strong>sibility 9.53, 10.20<br />
cosmetics 2.28, 3.9<br />
counterfactuals 1.16–1.18<br />
crop impact fund 9.68<br />
crowded-out alternatives 1.26, 1.28, 1.31<br />
crowdsourcing 9.50, Box 9.3<br />
cultivati<strong>on</strong> analysis 2.38, 5.11<br />
Darwinian evoluti<strong>on</strong> 4.12<br />
David, Paul 1.2, 2.33, 3.23<br />
dedicated biotechnology firms (DBFs) 9.10–<br />
9.12<br />
dehumanising c<strong>on</strong>sequences 2.34, 4.16<br />
deliberative mapping 5.36<br />
deliberative polling 5.37<br />
democracy 5.25<br />
Department for Business, Innovati<strong>on</strong> and Skills<br />
(BIS) 7.14, 7.50, 7.52, 7.54, 10.17<br />
I N D E X<br />
199